Hematology/Oncology

Top Story

FDA advisory committee expresses support for L-glutamine for sickle cell disease

May 24, 2017

An FDA panel today expressed its support for the approval of L-glutamine powder in the treatment of sickle cell disease.

The Oncologic Drugs Advisory Committee (ODAC) voted 10-3 in favor of Emmaus Medical’s new drug application for oral L-glutamine powder for chronic use in adults and children age 5 years and older with sickle cell disease.

Congressional Budget Office estimates $119 billion in savings over 10 years for House-passed AHCA

May 24, 2017
The Congressional Budget Office — a non-partisan scoring agency — and the staff of the Joint Committee on Taxation released its cost estimate for the…
Perspective

Prescription drug prices rose nearly 10% in 2016

May 24, 2017
The cost of prescription drugs increased by 8.77% last year, the fourth consecutive year drug prices have gone up, according to data from the Truveris National Drug…
FDA News

FDA grants priority review to Opdivo for advanced liver cancer

May 24, 2017
The FDA granted priority review to nivolumab for the treatment of hepatocellular carcinoma, according to the drug’s manufacturer. The designation applies to use of…
In the Journals

High-risk pools may raise health care costs for all Americans

May 24, 2017
Reinstituting high-risk pools as a state option as part of the American Health Care Act that was recently passed by the U.S. House of Representatives would move health…
More News Headlines »
CME

Immune Checkpoint Inhibitors for Advanced Melanoma: Clinical Updates and Multidisciplinary Strategies

This activity is supported by an educational grant from Bristol-Myers Squibb.

Incidence rates of melanoma in the United States continue to rise, with an estimated 87,110 new cases being diagnosed…
More »
Video
Meeting News

VIDEO: Managing immune-related adverse events requires multidisciplinary approach

April 13, 2017
More »
Featured
ASCO Annual Meeting

ASCO Annual Meeting

CME

Immune Checkpoint Inhibitors for Advanced Bladder Cancer: Applying Clinical Advances and Elucidating Best Practices

This activity is supported by an educational grant from Merck & Co, Inc.

Advances in immunology and the advent of immune checkpoint blockade inhibition for advanced bladder cancer are poised…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement